Equibles does not estimate personal net worth.
Get an email with a short summary when Alnylam Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get ALNY alertsAlnylam Pharmaceuticals, Inc. reported in an 8-K filed June 18, 2025 that Pushkal Garg, M.D. was appointed Executive Vice President, Chief Research and Development Officer, effective June 12, 2025. Pushkal Garg, M.D. has spoken on 1 earnings call and 1 other investor event across 1 company, most recently for Alnylam Pharmaceuticals, Inc. on September 8, 2026. Alnylam Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Alnylam Pharmaceuticals, Inc. includes Yvonne Greenstreet (CEO and COO), Yvonne L. Greenstreet (CEO, COO and Board Member), Amy W. Schulman (Chairman and Board Member) and 7 others.
“the Committee approved (i) the appointment of Pushkal Garg, M.D., the Company's current Chief Medical Officer, Executive Vice President, Development and Medical Affairs, to the position of Executive Vice President, Chief Research and Development Officer”
“So, look, I think the ESC presentations around Cardiac Transform were quite informative, right? I think a number of things that we think really point, unfortunately, to why the trial didn't succeed as anticipated.”
“Alnylam undoubtedly has one of the most robust pipelines in biotech, with over 25 clinical programs spanning multiple therapeutic areas across rare, specialty, and prevalent indications, representing a tremendous opportunity to improve patient health and create value in the years ahead.”
2025-06-12–present
Biotechnology · Healthcare
